HNRNPA2/B1 is found to be overexpressed in endocrine-resistant breast cancer cells, and this leads to upregulation of miR-1266-5p, miR-1268a and miR-671-3p, as well as reductions in levels of miR-29a-3p, miR29b-3p and miR-222 which, collectively, is linked to a reduction in the sensitivity of such cells to cancer drugs 4-hydroxytamoxifen and fulvestrant [66]. The gene discussed is HNRNPA2B1; the disease is breast carcinoma.